<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307824</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0647</org_study_id>
    <secondary_id>2017-A01405-48</secondary_id>
    <nct_id>NCT03307824</nct_id>
  </id_info>
  <brief_title>Operative Time During the Use of the Synthetic Glue IFABONDTM in Laparoscopic Sacrocolpopexy</brief_title>
  <acronym>Procolle 2</acronym>
  <official_title>A Multicenter Randomized Study on Operative Time When Using IFABOND™ Synthetic Glue in Laparoscopic Sacrocolpopexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopic sacrocolpopexy has now become the gold standard technique for correction of
      anterior and apical prolapse. In order to provide an alternative to stapling system and
      sutures involving vaginal erosion and shrinkage phenomena, there is a technique to fix
      material meshes by the use of a liquid, tissue, synthetic adhesive and sterile. The
      investigator hypothesizes that the use of IFABOND ™ adhesive in laparoscopic sacrocolpopexy
      significantly reduces the time of surgery compared to the classic suture technique. The
      prospective, randomized, multicenter study therefore aims to compare the time of surgery when
      using the IFABOND™ synthetic adhesive and the technique by sutures to fix material meshes in
      laparoscopic sacrocolpopexy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">November 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of surgery</measure>
    <time_frame>Day 0</time_frame>
    <description>time of surgery in minutes (measured by chronometers)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage prolapse correction failure</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>A correction failure correspond to a patient with stage ≥ II prolapse on the POP-Q classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage prolapse correction failure</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>A correction failure correspond to a patient with stage ≥ II prolapse on the POP-Q classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage prolapse correction failure</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>A correction failure correspond to a patient with stage ≥ II prolapse on the POP-Q classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>at 1 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>at 12 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>at 24 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>at day 0</time_frame>
    <description>assessed by visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by the questionnaires Short Form Health Survey-12 (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by the questionnaires Pelvic Floor Distress Inventory -20 (PFDI-20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by the questionnaires Pelvic Floor Impact Questionnaire-7 (PFIQ-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by the questionnaires Patient Global Impression of Improvement (PGI-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by the questionnaires SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by the questionnaires PFDI-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by the questionnaires PFIQ-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by the questionnaires PGI-I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by the questionnaires SF-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by the questionnaires PFDI-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by the questionnaires PFIQ-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by the questionnaires PGI-I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sexuality score</measure>
    <time_frame>at 1 months post-surgery</time_frame>
    <description>assessed by the questionnaire french version of Pelvic Organ Prolapse/Incontinence Sexual Questionnaire (PISQ-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sexuality score</measure>
    <time_frame>at 12 months post-surgery</time_frame>
    <description>assessed by the questionnaire PISQ-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sexuality score</measure>
    <time_frame>at 24 months post-surgery</time_frame>
    <description>assessed by the questionnaire PISQ-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of dyspareunia</measure>
    <time_frame>at 1 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of dyspareunia</measure>
    <time_frame>at 12 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of dyspareunia</measure>
    <time_frame>at 24 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of urinary incontinence</measure>
    <time_frame>at 1 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of urinary incontinence</measure>
    <time_frame>at 12 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of urinary incontinence</measure>
    <time_frame>at 24 months post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Prolapse</condition>
  <arm_group>
    <arm_group_label>IfabondTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the synthetic glue IfabondTM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sutures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glue-Free Suture Technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synthetic glue IfabondTM</intervention_name>
    <description>Use of the synthetic glue IfabondTM</description>
    <arm_group_label>IfabondTM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glue-Free Suture Technique</intervention_name>
    <description>Suture Technique</description>
    <arm_group_label>sutures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman aged 18 years or more

          -  Stage III or IV medial and/or anterior genital prolapse on the Pelvic Organ Prolapse
             Quantification (POP-Q) classification (hysterocele and/or cystocele) requiring
             surgical correction

          -  Patient requesting surgery for the trouble caused by the prolapse

        Exclusion Criteria:

          -  Prolapse of POP-Q stage &lt;III or without functional impact

          -  Unacceptable postoperative risk disclosed on interview: coagulation disorder, immune
             disorder, evolutive disease, etc.

          -  Impaired lower-limb range of motion preventing positioning for surgery

          -  Pregnancy or intended pregnancy during study period

          -  Evolutive or latent infection or signs of tissue necrosis on clinical examination

          -  Non-controlled diabetes (glycated haemoglobin &gt;8%)

          -  Treatment impacting immune response (immunomodulators), ongoing or within previous
             month

          -  History of pelvic region radiation therapy, at any time

          -  History of pelvic cancer

          -  Non-controlled evolutive spinal pathology

          -  Known hypersensitivity to one of the implant components (polypropylene)

          -  Cyanoacrylate hypersensitivity

          -  Formaldehyde hypersensitivity

          -  Inability to understand information provided

          -  No national health insurance cover; prisoner, or ward of court
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Géry LAMBLIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynaecology Department, Hôpital Femme Mère Enfant, HCL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Géry LAMBLIN, MD</last_name>
    <phone>472 35 58 71</phone>
    <phone_ext>+33</phone_ext>
    <email>gery.lamblin@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie MORET</last_name>
    <email>stephanie.moret@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynaecology Department, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géry LAMBLIN, MD</last_name>
      <phone>472 35 58 71</phone>
      <phone_ext>+33</phone_ext>
      <email>gery.lamblin@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie MORET</last_name>
      <email>stephanie.moret@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Géry LAMBLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gautier CHENE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CHABERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laparoscopic Surgery</keyword>
  <keyword>synthetic glue IFABONDTM</keyword>
  <keyword>time of surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

